WHO Releases Latest Report on Antibacterial Development The World Health Organization (WHO) has published its most recent assessment of antibacterial agents, encompassing antibiotics in various stages of clinical and preclinical development worldwide. The report reveals a notable increase in the…
A pivotal debate titled “How to Defeat Aging,” hosted by Open Longevity at the Foresight Institute on May 27, 2024, concluded with an unexpected outcome that shed light on the evolving landscape of rejuvenation biotechnology. The event featured Dr. Aubrey…
Sibylla Biotech and The University of Texas MD Anderson Cancer Center have announced a strategic collaboration to discover and develop novel small-molecule cancer therapies called Folding Interfering Degraders (FIDs). These therapies disrupt the proper folding of target proteins, leading to…
The European Commission has approved Alecensa® (alectinib) monotherapy as an adjuvant treatment for adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who are at high risk of recurrence (Stage IB [≥4 cm]–IIIA NSCLC [7ᵗʰ edition UICC/AJCC])…
Geron Corporation (Nasdaq: GERN), a biopharmaceutical company dedicated to revolutionizing blood cancer treatment, has received FDA approval for RYTELO™ (imetelstat). This approval is specifically for treating adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia…
Genentech, a member of the Roche Group, shared today groundbreaking 5-year findings reaffirming the lasting effectiveness and safety of Evrysdi® (risdiplam) in children diagnosed with Type 1 spinal muscular atrophy (SMA). These insights stem from the open-label extension of the…
Today marks the launch of “Refer a Friend,” a new feature from Allē, Allergan Aesthetics’ Loyalty Rewards Program. Allē members can now invite friends and family to join, allowing both parties to save on Allergan Aesthetics products and treatments from…
AbbVie announced that RINVOQ® (upadacitinib) is now approved in the U.S. for treating pediatric patients aged two years and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA), who have not responded adequately or are intolerant to…
Labcorp, a renowned provider of cutting-edge laboratory services globally, is set to unveil multiple abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4, 2024. The presentations will underscore Labcorp’s…
The European Commission (EC) has granted marketing authorization, maintaining orphan designation, for QALSODY® (tofersen) to treat amyotrophic lateral sclerosis (ALS) in adults associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS). QALSODY marks the first approved therapy in…
Sanofi Launches Action 2024: Global Employee Shareholder Plan Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, offering approximately 80,000 employees across 56 countries the opportunity to participate. Now in its 10th year, this program underscores Sanofi’s…
Eli Lilly and Company announced today a significant increase in investment for its Lebanon, Indiana, manufacturing site. The company has committed an additional $5.3 billion, bringing the total investment to $9 billion. This expansion will boost Lilly’s capacity to produce…
